Nityam Rathi

Nityam Rathi

Auto-generated profile, based on publicly available information

Nityam Rathi

Glickman Urological and Kidney Institute Cleveland Clinic Cleveland Ohio USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in BJU International
Verified
Journal Article
Open access
SCSteven C. Campbell
Steven C. Campbell
JCJack A. Campbell
Jack A. Campbell
CMCarlos Munoz‐Lopez
Carlos Munoz‐Lopez
NRNityam Rathi
Nityam Rathi
YYYosuke Yasuda
Yosuke Yasuda
WAWorapat Attawettayanon
Worapat Attawettayanon
Objective: To provide a narrative review of the major advances regarding ischaemia and functional recovery after partial nephrectomy (PN), along with the ongoing controversies. Methods: Key articles reflecting major advances regarding ischaemia and functional recovery after PN were identified. Special emphasis was placed on contributions that changed perspectives about surgical management. Priority was also placed on randomized trials of off‐clamp vs on‐clamp cohorts. Results: A decade ago, ‘Every minute counts' was published, showing strong correlations between duration of ischaemia and development of acute kidney injury (AKI) and chronic kidney disease after clamped PN. This reinforced perspectives that ischaemia was the main modifiable factor that could be addressed to improve functional outcomes and helped spur efforts towards reduced or zero ischaemia PN. These approaches were associated with strong functional recovery and some peri‐operative risk, although they were generally safe in experienced hands. Further research demonstrated that, when parenchymal volume changes were incorporated into the analyses, ischaemia lost statistical significance, and percent parenchymal volume saved proved to be the main determinant. Cold ischaemia was confirmed to be highly protective, and limited warm ischaemia also proved to be safe. The reconstructive phase of PN, with avoidance of parenchymal devascularization, appears to be most important for functional outcomes. Randomized trials of on‐clamp vs off‐clamp PN have shown minimal impact of ischaemia on functional recovery. Conclusions: The past decade has witnessed great progress regarding functional recovery after PN, with many lessons learned. However, there are still unanswered questions, including: What is the threshold of warm ischaemia at which irreversible ischaemic injury begins to develop? Are some cohorts at increased risk for AKI or irreversible ischaemic injury? and Which patients should be prioritized for zero‐ischaemia PN?

1 August 2020 in European Urology Oncology
Verified
Journal Article
Open access
FDFrede Donskov
Frede Donskov
WXWanling Xie
Wanling Xie
AOAnders Overby
Anders Overby
CWConnor Wells
Connor Wells
AFAnna P. Fraccon
Anna P. Fraccon
DHDaniel Y.C. Heng
Daniel Y.C. Heng
Patients with metastatic renal cell carcinoma (mRCC) may present with primary metastases (synchronous disease) or develop metastases during follow-up (metachronous disease). The impact of time to metastasis on patient outcome is poorly characterised. To characterise overall survival (OS) and time to treatment failure (TTF) based on time to metastasis in mRCC patients treated with targeted therapy (tyrosine kinase inhibitors [TKIs]). We used the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) to compare synchronous (metastases within ≤3 mo of initial diagnosis of cancer) versus metachronous disease (evaluated by >3-12 mo, >1-2 yr, >2-7 yr, and >7 yr intervals). OS and TFF were assessed using Kaplan-Meier curves. Cox multivariable regressions analyses (MVAs) were adjusted for baseline factors. Of 7386 patients with mRCC treated with first-line TKIs, 3906 (53%) and 3480 (47%) had synchronous and metachronous metastasis, respectively. More patients with synchronous versus metachronous disease had higher T stage (T1-2: 19% vs 34%), N1 disease (21% vs 6%), presence of sarcomatoid differentiation (15.8% vs 7.9%), Karnofsky performance status 3-12 mo, >1-2 yr, >2-7 yr, and >7 yr correlated with poor TTF (5.6 mo vs 7.3, 8.0, 10.8, and 13.3 mo, p < 0.0001) and poor OS (median 16.7 mo vs 23.8, 30.2, 34.8, and 41.7 mo, p < 0.0001). In MVAs, the adjusted hazard ratios (95% confidence intervals) were 1.00 (reference), 0.98 (0.90-1.06), 0.81 (0.73-0.91), 0.74 (0.68-0.81), and 0.60 (0.54-0.67), respectively, for OS (p < 0.0001), and 1.00 (reference), 0.99 (0.92-1.06), 0.98 (0.90-1.07), 0.83 (0.77-0.89), and 0.66 (0.60-0.72), respectively, for TTF (p < 0.0001). Data were collected retrospectively. Timing of metastases after initial RCC diagnosis may impact the outcomes from targeted therapy in mRCC. We looked at the impact of the timing of metastatic outbreak on survival outcomes in kidney cancer patients treated with targeted therapy. We found that the longer time to metastatic development was associated with improved outcome.

1 October 2018 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
AHAndrew Hahn
Andrew Hahn
CFCamryn Froerer
Camryn Froerer
SVSidney VanAlstine
Sidney VanAlstine
NRNityam Rathi
Nityam Rathi
EBErin B. Bailey
Erin B. Bailey
NANeeraj Agarwal
Neeraj Agarwal

19 April 2023 in BJU International
Verified
Journal Article
Closed access
CMCarlos Munoz‐Lopez
Carlos Munoz‐Lopez
KLKieran Lewis
Kieran Lewis
WAWorapat Attawettayanon
Worapat Attawettayanon
YYYosuke Yasuda
Yosuke Yasuda
JAJoão Pedro Emrich Accioly
João Pedro Emrich Accioly
SCSteven C. Campbell
Steven C. Campbell

5 May 2022 in European Urology Open Science
Verified
Journal Article
Open access
NRNityam Rathi
Nityam Rathi
YYYosuke Yasuda
Yosuke Yasuda
DPDiego Aguilar Palacios
Diego Aguilar Palacios
WAWorapat Attawettayanon
Worapat Attawettayanon
JLJianbo Li
Jianbo Li
SCSteven C. Campbell
Steven C. Campbell
While partial nephrectomy (PN) is generally preferred for localized renal cell carcinoma (RCC), radical nephrectomy (RN) is occasionally required. A new-baseline glomerular filtration rate (NBGFR) >45 ml/min/1.73 m2 after kidney cancer surgery is associated with strong survival outcomes. If NBGFR after RN will be above this threshold and the tumor has increased oncologic potential, RN may be a relevant consideration. Predicting NBGFR, defined as the GFR at 3–12 mo after RN, has been challenging owing to omission of two important parameters: split renal function (SRF) and renal function compensation (RFC). Our objective was to evaluate a simple SRF-based model in comparison to five published non–SRF-based models using data from a retrospective cohort of 445 RN patients. SRF was obtained via readily available semiautomated software (FUJIFILM Medical Systems) that provides differential parenchymal volume analysis on the basis of preoperative imaging. Our conceptually simple and clinically implementable SRF-based model more accurately predicts NBGFR after RN than five published non–SRF-based models (all p < 0.01). The SRF-based model also improved prediction of the clinically relevant threshold of NBGFR >45 ml/min/1.73 m2 (all p < 0.05). We validated a novel approach for more accurate prediction of kidney function after removal of one kidney. Our approach can be used in clinical and practice and will help in making decisions on full or partial removal of a kidney for kidney cancer.

14 February 2024 in BJU International
Verified
Journal Article
Closed access
AKAkira Kazama
Akira Kazama
WAWorapat Attawettayanon
Worapat Attawettayanon
CMCarlos Munoz‐Lopez
Carlos Munoz‐Lopez
NRNityam Rathi
Nityam Rathi
KLKieran Lewis
Kieran Lewis
SCSteven C. Campbell
Steven C. Campbell